公开(公告)号：US20240109970A1

公开(公告)日：2024-04-04

申请号：US18477140

申请日：2023-09-28

Applicant: Horizon Therapeutics Ireland DAC

Inventor： Elizabeth H.Z. THOMPSON ,  Jeffrey Wayne SHERMAN

IPC: C07K16/28 ,  A61P27/02

CPC classification number: C07K16/2863 ,  A61P27/02 ,  A61K2039/545 ,  C07K2317/76

Abstract: Described herein is a method of treating an individual with inactive thyroid eye disease (TED), the method comprising administering to an individual with inactive or chronic TED an insulin-like growth factor 1 receptor (IGF1R) inhibitor, thereby treating the inactive or chronic TED.

公开(公告)号：US20240091338A1

公开(公告)日：2024-03-21

申请号：US18115556

申请日：2023-02-28

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alfredo Nicosia ,  Ricardo Cortese ,  Alessandra Vitelli

IPC: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  A61K2039/545

Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.

公开(公告)号：US20240083989A1

公开(公告)日：2024-03-14

申请号：US18230480

申请日：2023-08-04

Applicant: Annexon, Inc. ,  The Regents of the University of California

Inventor： Susanna Rosi ,  Karen Krukowski ,  Ted Yednock ,  Sethu Sankaranarayanan

IPC: C07K16/18 ,  A61P25/00 ,  G01N33/573 ,  G01N33/58

CPC classification number: C07K16/18 ,  A61P25/00 ,  G01N33/573 ,  G01N33/58 ,  A61K2039/545

Abstract: The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.

公开(公告)号：US20240082396A1

公开(公告)日：2024-03-14

申请号：US18486230

申请日：2023-10-13

Applicant: Genentech, Inc.

Inventor： Jane L. GROGAN

IPC: A61K39/395 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/00 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N15/113 ,  C12N15/115

CPC classification number: A61K39/39558 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/193 ,  A61K38/20 ,  A61K38/217 ,  A61K39/0011 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/001113 ,  A61K39/001119 ,  A61K39/001124 ,  A61K39/001128 ,  A61K39/001129 ,  A61K39/001138 ,  A61K39/00114 ,  A61K39/001141 ,  A61K39/001166 ,  A61K39/00117 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/30 ,  C12N15/1138 ,  C12N15/115 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/545 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/76 ,  C12N2310/11 ,  C12N2310/12 ,  C12N2310/14 ,  Y02A50/30

Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.

公开(公告)号：US20240082380A1

公开(公告)日：2024-03-14

申请号：US18218459

申请日：2023-07-05

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lisa Purcell ,  Neil Graham ,  Andrew J. Murphy ,  Robert Evans

IPC: A61K39/02 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  C07K14/715 ,  C07K16/12 ,  C07K16/28

CPC classification number: A61K39/099 ,  A61K39/001119 ,  A61K39/0016 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  C07K14/7155 ,  C07K16/1225 ,  C07K16/28 ,  C07K16/2866 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/55527 ,  A61K2039/57 ,  A61K2039/622 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76 ,  Y02A50/30

Abstract: The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody in combination with said vaccine. In certain embodiments, the methods of the present invention are used to afford enhanced protection to an infectious disease such as whooping cough.

公开(公告)号：US11926669B2

公开(公告)日：2024-03-12

申请号：US18340722

申请日：2023-06-23

Applicant: HANALL BIOPHARMA CO., LTD. ,  Immunovant Sciences GmbH

Inventor： William Louis Macias ,  Su Liang ,  Hyeakyung Ahn ,  Haeyoung Yong ,  Mijin Jung ,  Minho Yoon ,  Eunsun Kim ,  Seungkook Park ,  Hyeeun Shim

IPC: C07K16/00 ,  A61P37/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/283 ,  A61P37/06 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.

公开(公告)号：US20240076394A1

公开(公告)日：2024-03-07

申请号：US18039473

申请日：2021-12-02

Applicant: Seagen Inc.

Inventor： Ryan A. HEISER ,  Bryan M. GROGAN

IPC: C07K16/28 ,  A61P35/04

CPC classification number: C07K16/2875 ,  A61P35/04 ,  A61K2039/545 ,  C07K2317/565

Abstract: Provided herein are anti-CD30 antibody-drug conjugates and methods of using the same to modulate the immune response in a subject.

公开(公告)号：US20240067736A1

公开(公告)日：2024-02-29

申请号：US18143749

申请日：2023-05-05

Applicant: Janssen Biotech, Inc.

Inventor： Sheri Moores

IPC: C07K16/28 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2863 ,  A61K45/06 ,  A61P35/00 ,  C07K16/303 ,  A61K2039/545

Abstract: The present disclosure provides methods of treating liver cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody.

公开(公告)号：US11913013B2

公开(公告)日：2024-02-27

申请号：US17389421

申请日：2021-07-30

Applicant: The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services ,  Sabin Vaccine Institute

Inventor： Nancy J. Sullivan ,  Gary J. Nabel ,  Clement Asiedu ,  Cheng Cheng ,  Alfredo Nicosia ,  Riccardo Cortese ,  Virginia Ammendola ,  Stefano Colloca

IPC: C12N15/86 ,  C12N15/861 ,  C07K14/08 ,  A61K39/12 ,  C07K14/005 ,  A61K39/00 ,  C12N15/863 ,  C12N7/00

CPC classification number: C12N15/86 ,  A61K39/12 ,  C07K14/005 ,  C07K14/08 ,  C12N15/861 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  C12N7/00 ,  C12N15/8636 ,  C12N2710/10341 ,  C12N2710/10343 ,  C12N2710/24111 ,  C12N2710/24141 ,  C12N2760/14111 ,  C12N2760/14134

Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).

公开(公告)号：US20240058430A1

公开(公告)日：2024-02-22

申请号：US17818548

申请日：2022-08-09

Applicant: GEG TECH

Inventor： Nicolas GRANDCHAMP

IPC: A61K39/00

CPC classification number: A61K39/0005 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/543 ,  A61K2039/545

Abstract: A method of vaccinating a subject in need thereof, which includes administering to the subject a ribonucleic acid (RNA) molecule including, from 5′ to 3′: an RNA Booster sequence that includes or is the following ribonucleic acid sequence mmsknkkkm, wherein: “m” indicates an adenine (a) or cytosine (c); “s” indicates a guanine (g) or a cytosine (c); “k” indicates a guanine (g) or a uracyl (u); “n” indicates any nucleotide; and a sequence of interest encoding at least one antigen.